The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)" aimed at promoting exploratory studies on how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. The initiative seeks to investigate the mechanisms through which these agents may affect cancer risk, especially concerning obesity-related cancers, rather than focusing solely on short-term outcomes like weight loss and diabetes management. With a funding ceiling of $275,000 over a two-year period, this opportunity is open to a diverse range of eligible applicants, including various educational institutions and community organizations. Interested parties should submit their applications by January 7, 2027, and can find more information and submission guidelines at the NIH grants website or by contacting grantsinfo@nih.gov.